Official UK procurement notice
NHS National Framework for Transition products commencing 1 October 2024
Authority: NHS England (Central government)
Re-procurement openNHS National Framework for Lenvatinib · bids close
What is being bought2 lots · detail below
Published requirement descriptionProject title: NHS National Framework for Transition products commencing 1 October 2024<br/>Offer reference number: CM/TNS/24/5712<br/>Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months.<br/>Potential periods of call-offs under the framework agreement:<br/> <br/>CM/TNS/24/5712/01 - Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets<br/>Lot 1 CESW: 01/10/2024 to 30/09/2025 (12 months) <br/>Lot 2 NWLN: 01/10/2024 to 30/09/2025 (12 months) <br/>Lot 3 LSNE: 01/10/2024 to 31/05/2026 (20 months) <br/><br/>CM/TNS/24/5712/02 - Imatinib<br/>Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months) <br/><br/>Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England
CPV: Pharmaceutical products
How this framework works
From the published notice- Bids received
- 25 bids on the busiest of 2 lots · 12 suppliers appointed
- Framework period
- 1 yr 8 mo from 1 Oct 2024
Lots and requirements (2)Procurement structure
2 lots · all with a published valueLot #1CM/TNS/24/5712/01AwardedPublished value£131,150,000
CM/TNS/24/5712/01 - Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets<br/>Lot 1 CESW: 01/10/2024 to 30/09/2025 (12 months) <br/>Lot 2 NWLN: 01/10/2024 to 30/09/2025 (12 months) <br/>Lot 3 LSNE: 01/10/2024 to 31/05/2026 (20 months) Additional information: CM/TNS/24/5712/01 - Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets<br/>Lot 1 CESW: 01/10/2024 to 30/09/2025 (12 months) <br/>Lot 2 NWLN: 01/10/2024 to 30/09/2025 (12 months) <br/>Lot 3 LSNE: 01/10/2024 to 31/05/2026 (20 months)
Lot #2CM/TNS/24/5712/02AwardedPublished value£810,000
CM/TNS/24/5712/02 - Imatinib<br/>Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months) Additional information: CM/TNS/24/5712/02 - Imatinib<br/>Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months)
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
- “NHS National Framework for Transition products commencing 1 October 2024” is a framework: the contest is a place on its panel, not a single contract.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Open procedure
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use this agreement
- Not stated in the notice; call-off rights may be limited to the establishing authority
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- No (one-off requirement)
- First published
- 26 Jun 2024, 14:59 BST
- Last source update
- 17 Oct 2024, 16:47 BST
- Award evaluation window
- 29 Jul 2024 – …
- Authority reference
CM/TNS/24/5712- FTS notice number
2024/S 000-033646- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-0472c3Find a Tender
- Electronic trading
- electronic ordering · electronic payment
Publisher note: RESPONDING TO THIS NOTICE;<br/>Any supplier may be disqualified who does not respond to the following in the requisite manner:<br/>1) Submission of expression of interest and procurement specific information. This procurement exercise will be conducted on the eTendering portal at http://health.atamis.co.uk<br/>Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested) through the eTendering portal as follows:<br/>1.1) If not already registered, Candidates should register on the eTendering portal at http://health.atamis.co.uk and click the link to register:<br/>- agree to the user agreement<br/>- populate company details<br/>1.2) Once registered, candidates must register interest as follows:<br/>- log to the portal<br/>- select "Find Opportunities" from the supplier home screen, use the "Sort by:" facility to find this opportunity and select the bold blue title to select<br/>- review opportunity details and click "Register Interest"<br/>- as you select the opportunity, you can review documents, send clarification messages, submit the response or decline to respond (if you decide not to participate in the opportunity)<br/>1.3) There is a supplier user guide on using the system and Candidates can contact the Atamis helpdesk at [email protected] or by calling 0800 9956035 for technical assistance when completing responses.<br/>2) General supplier information.<br/>To manage and assess supplier information the Contracting Authority requests candidates provide their<br/>company profile in the Government's Supplier Registration Service (which has replacedsid4gov), as follows:<br/>2.1) If not already registered (the previous sid4gov password, login and details will still<br/>be on the system), candidates must go to the following web page https://supplierregistration.cabinetoffice.gov.uk<br/>and select "Register" at the top of the page.<br/>Key in details as requested to search for your company. If you do not have a D-U-N-S®Number, click on the link at the right of the page to obtain a number from D&B.<br/>Candidates must obtain a Dun & Bradstreet (D&B) D-U-N-S® Number to enable registration on the system.<br/>2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise.<br/>D&B data will be supplied automatically by D&B.<br/>2.3) For further help or information concerning this telephone +44 (0) 161 413 7982 or via the<br/>message function on the website.<br/>OTHER CONTRACTING AUTHORITIES<br/>The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.
How it was run
Official noticeTender documents are also served through a separate tool: https://health-family.force.com/s/Welcome ↗
- Appointment period ends
- 29 Jul 2024, 13:00 BST
- Submission channel
- {"electronicSubmission","written"}
- Accepted languages
- en
- Bids opened
- 29 Jul 2024, 13:00 BST
Timeline
29 Jul 2024 → 27 Oct 2024 · 5 dates- Admission / appointment period endsperiod end, not a bid countdown29 Jul 2024, 13:00 BST
- Bids opened29 Jul 2024, 13:00 BST
- Contract starts1 Oct 2024, 00:00 BST
- Notice published17 Oct 2024, 16:47 BST
- Bids must remain valid until27 Oct 2024, 23:59 GMT
Notice history
1 event · 2 releases on Find a Tender- Status changed to complete17 Oct 2024, 16:47 BST
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast13 suppliers are admitted to this framework without individual award values or dates, see the supplier list below.
Contracts
All 13 of these contracts carry the same published figure, £1, the framework's maximum for the whole notice, not each contract's own value. They are not eleven separate sums.
Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets
- Signed
- 30 Sept 2024
- Value
- ceiling above
- Period
- … – 31 May 2026
- Status
- active
Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets
- Signed
- 30 Sept 2024
- Value
- ceiling above
- Period
- … – 31 May 2026
- Status
- active
Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets
- Signed
- 30 Sept 2024
- Value
- ceiling above
- Period
- … – 31 May 2026
- Status
- active
Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets
- Signed
- 30 Sept 2024
- Value
- ceiling above
- Period
- … – 31 May 2026
- Status
- active
Imatinib Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months)
- Signed
- 30 Sept 2024
- Value
- ceiling above
- Period
- … – 30 Sept 2025
- Status
- active
Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets
- Signed
- 30 Sept 2024
- Value
- ceiling above
- Period
- … – 31 May 2026
- Status
- active
Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets
- Signed
- 30 Sept 2024
- Value
- ceiling above
- Period
- … – 31 May 2026
- Status
- active
Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets
- Signed
- 30 Sept 2024
- Value
- ceiling above
- Period
- … – 31 May 2026
- Status
- active
Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets
- Signed
- 30 Sept 2024
- Value
- ceiling above
- Period
- … – 31 May 2026
- Status
- active
Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets
- Signed
- 30 Sept 2024
- Value
- ceiling above
- Period
- … – 31 May 2026
- Status
- active
Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets
- Signed
- 30 Sept 2024
- Value
- ceiling above
- Period
- … – 31 May 2026
- Status
- active
Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets
- Signed
- 30 Sept 2024
- Value
- ceiling above
- Period
- … – 31 May 2026
- Status
- active
Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets
- Signed
- 30 Sept 2024
- Value
- ceiling above
- Period
- … – 31 May 2026
- Status
- active
Bid statistics published by the authority
| Lot | Bids | SME | VCSE | Valid bid range |
|---|---|---|---|---|
| 1 · CM/TNS/24/5712/01 | 25bids · 25 electronic · 25 from abroad | 14 | — | — |
| 2 · CM/TNS/24/5712/02 | 6bids · 6 electronic · 6 from abroad | 4 | — | — |
Contracting authority & participating public bodies
Dispute resolution & review bodies
- The High CourtReview body
Framework contractors & participating bidders
12 commercial parties on the notice- Accord-UK LtdFramework contractor
- Amarox LimitedFramework contractor
- Celix Pharma Ltd.Framework contractor
- Dr.Reddy's Laboratories (UK) LimitedFramework contractor
- Gilead Sciences LimitedFramework contractor
- Glenmark Pharmaceuticals Europe LimitedFramework contractor
- Mercury Pharmaceuticals LimitedFramework contractor
- Seacross Pharmaceuticals LtdFramework contractor
- Teva UK LimitedFramework contractor
- Thornton and Ross LtdFramework contractor
Show 2 more suppliers
- Tillomed Laboratories ltdFramework contractor
- Zentiva Pharma UK LtdFramework contractor
Official documents & specifications (2)
Official links; attachments are not copiedTender pack and attachments
- Economic and financial selection criteria
- Technical selection criteria